Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05552183 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, and PK of Pacritinib
A Phase 1 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05552183: Completed Phase 1 study, sponsored by CTI BioPharma.
NCT05552183 is a Phase 1 study that has completed, run by CTI BioPharma. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05552183, a Phase 1 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a Phase 1 study designed to assess the effect of hepatic insufficiency on the PK of pacritinib by study of 14-day BID dosing of pacritinib in subjects with moderate and severe hepatic impairment compared to healthy matched control subjects with normal liver function. Safety and tolerability of multiple day dosing of pacritinib in the subject populations will also be evaluated.
Interventions
- DRUG oral dose of 200 mg pacritinib twice daily (BID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2024-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05552183
The ClinicalTrials.gov registry entry for NCT05552183 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which oral dose of 200 mg pacritinib twice daily (BID) is the first listed.
NCT05552183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05552183 about?
NCT05552183 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and PK of Pacritinib". This is a Phase 1 study designed to assess the effect of hepatic insufficiency on the PK of pacritinib by study of 14-day BID dosing of pacritinib in subjects with moderate and severe hepatic impairment compared to healthy matched control subjects with normal liver function. Safety and tolerability ...
What is the current status of trial NCT05552183?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2022-12-12. Estimated completion is 2024-06-10.
What interventions are being tested in trial NCT05552183?
The interventions under investigation include: oral dose of 200 mg pacritinib twice daily (BID) (DRUG).
Who is sponsoring clinical trial NCT05552183?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.